SCYNEXIS, Inc. and Immune Design Corporation Collaborate on Innovative Process for Vaccine Production Technology

RESEARCH TRIANGLE PARK, NC--(Marketwired - April 10, 2013) - SCYNEXIS, Inc. announced today that Immune Design Corp. has selected SCYNEXIS as its chemical development and cGMP production partner for manufacture of Glucopyranosyl Lipid A (GLA).

Immune Design’s GLA is the first clinical stage synthetic TLR4 agonist with the demonstrated ability to enhance vaccine immunogenicity in humans. Clinical and preclinical studies have established that GLA has properties that may make it ideal for use as an adjuvant for prophylactic and therapeutic vaccines.

By joining forces, the teams have accomplished a major breakthrough, validating a new synthesis for GLA, within a short period of time.

“Partnering with SCYNEXIS, with its efficient and cost-effective chemistry synthesis process, moves us closer to delivering important vaccine products to those in need,” said Carlos Paya, M.D., Ph.D., President and Chief Executive Officer of Immune Design.

“We’re excited that our talented team provided the expertise and inventiveness, in partnership with Immune Design, to deliver this important compound,” said Yves Ribeill, Ph.D., President and Chief Executive Officer of SCYNEXIS. “At SCYNEXIS, we always welcome the opportunity to join forces and solve the challenges of complex chemistry projects while creating innovative solutions with our partners.”

SCYNEXIS’ contract research and development services include Integrated Pharmaceutical Solutions, Discovery Research and Integrated Parasitology.

About Immune Design Corporation
Immune Design is a privately held, clinical-stage biotechnology company based in Seattle, Washington, and formed in 2008 to bring together some of the world’s leaders in the field of molecular immunology to develop vaccines for the treatment and prevention of infectious and malignant disease. The company employs advanced and leading edge methods to precisely control the activation and context of antigen presentation by dendritic cells in order to shape the desired adaptive immune response. This goal is accomplished through the application of two proprietary technology platforms that activate the immune system by distinct mechanisms. Additional information can be found on the company’s website at www.immunedesign.com.

About SCYNEXIS
SCYNEXIS delivers innovative solutions to solve the toughest problems in drug discovery and development for our pharmaceutical, global health and life science partners. We have successfully delivered preclinical and clinical drug candidates to our customers across all major therapeutic indications and have developed our own proprietary cyclophilin inhibitor programs for the treatment of a broad range of diseases, including HCV, HBV and inflammation. Founded in 2000, SCYNEXIS is located in Research Triangle Park, North Carolina. Visit www.scynexis.com.